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Purpose: In the phase 3 DUO trial, duvelisib, an oral dual PI3K-δ,γ inhibitor, demonstrated significantly 
improved efficacy vs ofatumumab (median [m]PFS, 13.3 vs 9.9 months [HR, 0.52; P < .0001]; ORR, 74% 
vs 45% [P < .0001]), with a manageable safety profile in patients with relapsed/refractory (R/R) chronic 
lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). We report results from patients with 
progressive disease (PD) after ofatumumab who crossed over to duvelisib in the DUO trial. 
 
Experimental Design: Patients with radiographically confirmed PD after ofatumumab received duvelisib 
25 mg twice daily in 28-day cycles until PD, intolerance, death, or study withdrawal. The primary 
endpoint was ORR per investigator. Secondary endpoints included duration of response (DOR), PFS, and 
safety. 
 
Results: As of December 14, 2018, 90 ofatumumab-treated patients in the DUO trial prior to crossover 
had an ORR of 29%, mDOR of 10.4 months, and mPFS of 9.4 months. After crossover, 77% of patients 
(69/90) achieved a response, with an mDOR of 14.9 months and mPFS of 15.7 months. Patients with 
del(17p) and/or TP53 mutations had similar outcomes (ORR, 77% [20/26]; mPFS, 14.7 months). Notably, 
73% of patients (47/64) with disease previously refractory to ofatumumab achieved a response. The 
most frequent any-grade/grade 3/4 treatment-emergent adverse events were diarrhea (47%/23%), 
neutropenia (26%/23%), pyrexia (24%/4%), cutaneous reactions (23%/4%), and thrombocytopenia 
(10%/6%). 
 
Conclusion: Duvelisib demonstrated high response rates with good durability and a manageable safety 
profile in patients with R/R CLL/SLL who progressed on ofatumumab, including patients with high-risk 
disease and disease previously refractory to ofatumumab. 
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Despite the efficacy of agents recently approved for the treatment of patients with CLL, in many 
patients, the disease will develop resistance and progress, resulting in an urgent need for new effective 
and tolerable treatment options. Duvelisib is an oral, dual PI3K-δ,γ inhibitor that recently received US 
Food and Drug Administration approval as monotherapy in R/R CLL/SLL. In the registrational phase 3 
DUO trial, duvelisib demonstrated a significant improvement in efficacy vs ofatumumab in patients with 
R/R CLL/SLL. Following disease progression while receiving ofatumumab in DUO, patients could cross 
over to receive duvelisib in a crossover extension study. We show that duvelisib resulted in favorable 
outcomes and had a manageable safety profile in patients treated with duvelisib in this crossover study. 
These results confirm duvelisib as an effective treatment option in CLL/SLL, even in patients with high-
risk features, prior refractory disease, and disease progression on ofatumumab. 
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Despite recent approvals of several active novel agents for chronic lymphocytic leukemia (CLL), the 
disease remains incurable for most patients. Agents targeting Bruton tyrosine kinase (BTK) and BCL2 are 
efficacious for many patients with relapsed or refractory (R/R) CLL, yet many patients will develop 
resistance and progressive disease (PD) (1-5). As occurs with chemoimmunotherapy, high-risk genetic 
features such as 17p13.1 deletion (del(17p)) or TP53 somatic mutations confer a poorer prognosis with 
BTK and BCL2 inhibitor therapy (6-8). As such, there remains an urgent need to develop new effective 
and tolerable CLL/small lymphocytic lymphoma (SLL) treatment options, particularly for patients with 
high-risk disease. 
 
Duvelisib is an oral, dual PI3K-δ,γ inhibitor that directly targets malignant B cells and key signaling 
pathways in the tumor microenvironment (9-11). In preclinical studies, dual inhibition of PI3K-δ,γ with 
duvelisib was more effective at inhibiting CLL B cells and reducing the number of CLL-supporting cells in 
vivo than PI3K-δ inhibition alone (9,10). 
 
In early-phase clinical trials, duvelisib monotherapy demonstrated a manageable safety profile and 
clinically meaningful activity in patients with R/R hematologic malignancies, including CLL/SLL (12). In 
the randomized, open-label, registrational, phase 3 DUO trial (NCT02004522), the efficacy and safety of 
duvelisib 25 mg twice daily (BID) was compared with the anti-CD20 monoclonal antibody ofatumumab 
(13) in patients with R/R CLL/SLL (14). Duvelisib demonstrated a statistically significant improvement in 
progression-free survival (PFS) and overall response rate (ORR) compared with ofatumumab in patients 
with R/R CLL/SLL (median PFS [mPFS], 13.3 vs 9.9 months [hazard ratio, 0.52; P < .0001]; ORR, 74% vs 
45% [P < .0001]), with similar efficacy in patients with high-risk del(17p) or TP53 mutation (14). Duvelisib 
monotherapy demonstrated a consistent safety profile in this phase 3 trial compared with earlier trials, 
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with the most common toxicities observed being any-grade diarrhea, neutropenia, and pyrexia. In most 
cases, these toxicities were manageable with appropriate intervention via dose modifications and 
routine medical care (12,15-17). Duvelisib monotherapy was approved by the US Food and Drug 
Administration in September 2018 for the treatment of patients with R/R CLL/SLL after ≥ 2 prior 
therapies (12). 
 
The DUO crossover extension study (IPI-145-12; NCT02049515) is an open-label, phase 3 study that 
evaluated the efficacy and safety of duvelisib monotherapy in patients with R/R CLL/SLL who 
experienced PD while receiving ofatumumab in the DUO trial. We report the final results for this 
extension study. 
 
Patients and Methods 
Study design and treatment 
DUO crossover is a 2-arm, open-label, nonrandomized, optional, extension study of duvelisib and 
ofatumumab in patients with R/R CLL/SLL who had received treatment in the parent DUO study. 
Patients who exhibited radiographically confirmed PD by central review in the DUO trial had the option 
to subsequently receive the other study treatment (duvelisib or ofatumumab). 
 
The dose and regimen of duvelisib and ofatumumab were the same as those in the DUO trial (14). 
Patients receiving duvelisib were started at a dose of 25 mg BID in a 21-day treatment cycle followed by 
28-day treatment cycles until PD, unacceptable toxicity, death, or study withdrawal (whichever came 
first). Ofatumumab was administered per the approved product label for monotherapy in relapsed CLL 
at the time the DUO study was initiated and could not exceed the 12 doses (within 7 cycles), as 
described in the prescribing information (13). Pneumocystis jiroveci pneumonia (PJP) prophylaxis 
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concomitant with study drug treatment was required for all patients; trimethoprim/sulfamethoxazole 
was the most commonly used medication for PJP prophylaxis in the parent DUO study. Per protocol, 
antiviral prophylaxis was recommended to be implemented at the discretion of the treating investigator.  
 
The final study protocol, and its amendments, were approved by an Institutional Review 
Board/Independent Ethics Committee for each clinical trial site and conducted in accordance with the 
Declaration of Helsinki and the International Conference on Harmonization Guidelines for Good Clinical 
Practice. All patients provided written informed consent. 
 
Patient eligibility 
Eligible patients included all those who participated in the DUO study and experienced radiographically 
confirmed PD by central review prior to enrollment in the DUO crossover trial. Key inclusion and 
exclusion criteria were the same as those in the parent DUO study (14). Inclusion criteria included active 
CLL/SLL necessitating treatment per the International Workshop on CLL (iwCLL) criteria or measurable 
disease per the revised International Working Group (IWG), defined as ≥ 1 lymph node or tumor mass 
measuring > 1.5 cm by computed tomography (CT) scan; adequate renal and hepatic function; 
hemoglobin level ≥ 8.0 g/dL; and platelet count ≥ 10,000 μL with or without transfusion support. There 
was no eligibility requirement regarding neutrophil count. Exclusion criteria included prior treatment 
with BTK or PI3K inhibitors, refractoriness to prior ofatumumab therapy prior to enrollment in DUO, and 
a history of Richter transformation, prolymphocytic leukemia, or allogeneic stem cell transplant. 
 
Study endpoints and assessments 
The primary endpoint was ORR, as assessed by investigators, defined as complete response (CR), CR 
with incomplete marrow recovery (CRi), partial response (PR), or PR with lymphocytosis (PRwL), 
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according to the 2008 iwCLL (18) with modification for treatment-related lymphocytosis. Per protocol, a 
response of PRwL was limited to patients with lymphadenopathy as the only abnormal baseline group A 
criterion (no organomegaly and normal blood lymphocyte count, 4 x 109/L) who achieved a PR (≥ 50% 
reduction in lymphadenopathy) but had post-baseline isolated lymphocytosis. 
 
Secondary efficacy endpoints were PFS, defined as time from first dose to first documentation of 
investigator-assessed PD per iwCLL/IWG (18,19) criteria or death resulting from any cause, and DOR, 
defined as time from first response to PD or death. This study was not designed to detect differences in 
PFS among subgroups. 
 
Patients were followed up for overall survival (OS) for 6 years following randomization to the parent 
DUO study. Response assessments (including review of disease-associated symptoms) were performed 
every 4 cycles until cycle 12, every 6 cycles until cycle 24, and then every 6 cycles until PD, start of new 
anticancer therapy, or patient withdrawal. 
 
Local laboratories assessed lymphocyte counts. Central laboratories assessed prognostic markers and 
cytogenetics at baseline in the DUO study and did not re-evaluate on enrollment in the DUO crossover 
study. 
 
Safety was assessed at days 1 and 8 of cycle 1, days 1 and 15 of cycle 2, day 1 of cycles 3 to 7, then day 1 
of every even-numbered cycle of cycles 8 to 18 and every third cycle from cycle 21 thereafter until 30 
days from the last dose of study drug. Events were coded using Medical Dictionary for Regulatory 
Activities version 16.1. The severity of treatment-emergent adverse events (TEAEs) was assessed 
according to National Cancer Institute Common Terminology Criteria for Adverse Events v4.03 (20). 
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TEAEs were defined as any AE that emerged or worsened in the period from the first dose of study 
treatment through 30 days after the last dose of study treatment. 
 
Statistical methods 
ORR was analyzed as the proportion of patients achieving a best response of PR/PRwL or CR/CRi as 
determined by the investigator; the corresponding 95% CIs were calculated. PFS and duration of 
response, as determined by investigators, were estimated using Kaplan-Meier methods on all patients 
receiving duvelisib and all patients who achieved a response on duvelisib, respectively. OS was 
estimated using Kaplan-Meier methods on all patients receiving duvelisib. 
 
Results 
Patient baseline characteristics 
Between September 19, 2014, and July 17, 2017, 99 patients were enrolled at 43 clinical sites in 11 
countries and received duvelisib (n = 90) or ofatumumab (n = 9) within 3 months of PD in the DUO trial. 
This report focuses on the results in the 90 patients who crossed over from ofatumumab and received 
duvelisib 25 mg BID. 
 
The baseline characteristics of these 90 patients were similar to those of the overall population of 
patients reported in the DUO trial (14) (Table 1). Patients were predominately male (63%), with a 
median age of 68 years. Most patients (89%) had a baseline Eastern Cooperative Oncology Group 
performance status of 0 to 1. The median time from initial diagnosis was 7.1 years, and more than half 
of the patients had bulky disease (≥ 5-cm target lesion; 52%). A total of 22% of patients (9/41) had Rai 
stage III/IV disease at diagnosis (vs 49% of patients [21/43] at enrollment in the parent DUO study), and 
66% of patients (31/47) had Binet stage B or C disease at diagnosis (vs 100% [47/47] at enrollment in the 
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parent DUO study). Median baseline lymphocyte count was 14.4 × 109/L. Central laboratory 
determination of molecular features identified del(17p) and/or TP53 mutations in 29% of patients 
(del[17p], 22% [20/90]; TP53, 18% [16/90]; del(17p) and TP53, 11% [10/90]) and unmutated IGHV in 
72% of patients (65/90). 
 
The median number of prior therapies was 3 (range, 2-8), including ofatumumab received in the parent 
DUO study (Supplementary Table S1). Most patients previously received a monoclonal antibody (100%), 




The investigator-assessed ORR with duvelisib treatment after crossover was 77% (69/90); in the subset 
of patients with del(17p) and/or TP53 mutations, the ORR was also 77% (20/26) (Table 2). In all patients, 
responses were predominantly PR (61%): 10 patients (11%) achieved a PRwL and 4 (4%) achieved a CRi. 
Similar outcomes were observed in patients with del(17p) and/or TP53 mutations (PR, 58%; PRwL, 8%; 
CRi, 12%). The median time to response was 2.6 months (range, 1.5-10.7 months). The median duration 
of response was 14.9 months (95% CI, 9.0-18.6 months) for the total patient population and 11.3 
months (95% CI, 5.1-21.2 months) for the subset of patients with del(17p) and/or TP53 mutations (Table 
2). Response rates were higher for patients after crossing over to duvelisib compared with their prior 
response rates to ofatumumab in the DUO trial (Supplementary Table S2). Similar response rates were 
also observed in patients with bulky disease (≥ 5 cm) and in those with del(11q): ORR (n/N; 95% CI), 
bulky disease: 74% (35/47; 0.6-0.86); del(11q): 80% (16/20; 0.56-0.94). 
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Responses to duvelisib in the crossover study were also observed in patients whose disease did not 
respond to ofatumumab in the DUO trial (Table 2). Of 64 patients who were refractory to ofatumumab, 
47 (73%) achieved a response after crossing over to duvelisib, with the majority of these responses 
being PRs (63%). 
 
Reductions in lymph node tumor burden over time were generally accompanied by a decrease in 
absolute lymphocyte count (ALC) (Fig. 1A). Overall, 70 of 78 (90%) response-evaluable patients had 
> 50% reduction in target nodal lesions (Fig. 1B). Of those 70 patients with > 50% reduction, 71% had PR, 
13% had PRwL, 10% had stable disease, and 6% had CRi. Additionally, 82% of patients (74/90) 
experienced redistribution lymphocytosis, which occurred early, with a median time to onset of 1.1 
weeks (range, 0.7-89.7 weeks) and a median duration of 15.1 weeks (range, 1.1-127 weeks). The median 
time to resolution of first lymphocytosis (ALC less than or equal to baseline value or ALC < 5 × 109/L) was 
14.6 weeks (range, 2-87.3 weeks).  
 
Survival 
With a median overall follow-up of 13.5 months, mPFS per investigator assessment was 15.7 months in 
all patients who received duvelisib and 14.7 months in the subset of patients with del(17p) and/or TP53 
mutations (Fig. 2). In all patients, the estimated probability of being progression free at 6 months and 12 
months was 88% and 64%, respectively. In contrast, mPFS with ofatumumab before crossover was 9.4 
months in all patients and 9.1 months in patients with del(17p) and/or TP53 mutations (Supplementary 
Fig. S1). PFS with duvelisib after crossover was numerically longer in patients with del(11q) (vs those 
with no del(11q)) and in patients without trisomy 12 (vs those with trisomy 12); PFS was similar in 
patients with and those without bulky disease (Supplementary Fig. S2). All patients in the parent DUO 
study were followed up for survival for 6 years from randomization. In patients who received duvelisib 
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after crossover (n = 90), the median OS was 43 months (Supplementary Fig. S3), with an estimated 




The median duration of exposure to duvelisib was 43 weeks (range, 2-187 weeks), and 48% of patients 
received ≥ 12 cycles (≈ 1 year) of duvelisib, with a median of 11 cycles (range, 1-48 cycles). Hematologic 
TEAEs that occurred in > 5% of patients and nonhematologic TEAEs that occurred in ≥ 10% of patients 
are reported in Table 3. All patients treated with duvelisib experienced ≥ 1 TEAE. The most common 
any-grade hematologic TEAEs occurring in > 5% of patients were neutropenia (26%), thrombocytopenia 
(10%), and anemia (8%). The rate of febrile neutropenia was low (3%), and 23% of patients (21/90) 
received ≥ 1 administration of granulocyte colony-stimulating factor. The most common any-grade 
nonhematologic TEAEs occurring in ≥ 10% of patients included diarrhea (47%), pyrexia (24%), and rash 
(23%). Grade ≥ 3 TEAEs occurred in 89% of duvelisib-treated patients. The most common grade ≥ 3 
events were neutropenia and diarrhea (23% each) and colitis and pneumonia (11% each). Three patients 
had grade ≥ 3 PJP (2 who had self-discontinued PJP prophylaxis and 1 who was receiving prophylaxis 
with Bactrim™ [trimethoprim and sulfamethoxazole] at the time of onset), and 1 patient had grade ≥ 3 
cytomegaloviral pneumonia. TEAEs observed in this study were generally manageable with dose 
interruptions and reductions, which occurred in 65 (72%) and 18 (20%) patients, respectively. TEAEs 
resulting in treatment discontinuation occurred in 47 patients (52%), with colitis (n = 9), diarrhea (n = 8), 
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TEAEs of special interest (AESI) related to duvelisib were defined as infections, diarrhea, colitis, 
neutropenia, cutaneous reactions, transaminase elevations, and pneumonitis (13). Rates of grade ≥ 3 
events due to AESI are depicted in Fig. 3. Median time to onset of each AESI ranged from 2 to 7 months 
(colitis, 5.8 months; diarrhea, 5.5 months; pneumonitis, 6 months; pneumonia, 7.2 months; infections, 
3.2 months; transaminitis, 2.6 months; cutaneous reactions, 3.2 months). Ten of 42 patients with 
diarrhea, 5 of 13 patients with colitis, 6 of 25 patients with cutaneous reactions, and 1 of 1 patient with 
pneumonitis received steroid therapy, with resolution reported in the majority of patients at the time of 
data cutoff. 
 
Serious TEAEs are summarized in Supplementary Table S3. Serious hematologic TEAEs occurring in ≥ 2 
patients were febrile neutropenia, neutropenia, and pancytopenia. Serious nonhematologic TEAEs not 
due to PD occurring in ≥ 2 patients were bronchitis, pseudomonal sepsis, urinary tract infection, acute 
renal failure, respiratory failure, and maculopapular rash. Twelve patients (13%) died within 30 days of 
the last dose (Supplementary Table S4).  
 
As of the December 14, 2018, data cutoff, 79 patients (88%) had discontinued treatment with duvelisib, 
due to TEAEs (48%), PD (22%), death (7%), patient decision (3%), investigator decision (2%), protocol 
deviation (1%), or other reasons (4%) (Supplementary Table S5). Rates of discontinuation due to AESI 
are depicted in Fig. 3. 
 
Discussion 
Duvelisib monotherapy achieved robust and durable responses in patients with R/R CLL/SLL who had 
radiographically confirmed PD following ofatumumab monotherapy in the phase 3 DUO study (14). 
Patients with del(17p) and/or TP53 mutations and those refractory to ofatumumab had results 
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equivalent to those of the group as a whole. PFS with duvelisib was also favorable in light of the PFS that 
these same patients had while receiving ofatumumab (15.7 vs 9.4 months, respectively). In addition, the 
median OS and OS at 12 months were similar to those reported with duvelisib in the parent DUO study 
(median OS, 43 months vs not reached; 12-month OS, 82% vs 86%, respectively). 
 
The favorable efficacy observed with duvelisib in patients previously treated with ofatumumab in this 
study is similar to that reported in the parent DUO clinical trial (14) and is consistent with results from 
the phase 1 study of duvelisib in R/R CLL/SLL, in which approximately 95% of patients received prior 
rituximab (16). The efficacy of duvelisib monotherapy was similar to that reported for ibrutinib in the 
post–anti-CD20 setting (21). Furthermore, compared with a 77% ORR and 15.7 month median PFS in the 
duvelisib study reported here, a previous extension study in a similar patient population with idelalisib 
after rituximab demonstrated a 47.6% ORR and 6.9 month median PFS (22). Thus, duvelisib has been 
shown to be an attractive all-oral therapy option for patients with R/R CLL/SLL, providing improved 
durability of benefit over that of idelalisib without the need for infusional anti-CD20 therapy. 
 
The safety profile of duvelisib monotherapy was manageable via dose interruption or reduction in this 
study and was similar to that observed to date, which has not been affected by the number and type of 
previous therapies received (12). As typically observed with all CLL therapies, infections were relatively 
common with duvelisib, although the rate of febrile neutropenia was low at 3%. PJP prophylaxis is an 
important supportive measure for this therapy because 2 of 3 patients who had severe PJP on this study 
did not receive prophylaxis at the time of onset. Neutropenia and diarrhea were the most common 
severe (grade ≥ 3) AEs reported in 23% of duvelisib-treated patients, followed by colitis and pneumonia 
(11% each). Several of these prespecified AESI were known to be associated with PI3K inhibition and 
were observed with similar median times to onset than those reported for DUO (14,23). Occurrences of 
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infections, diarrhea, colitis, neutropenia, cutaneous reactions, alanine aminotransferase/aspartate 
aminotransferase elevations, and pneumonitis were generally manageable with early intervention, 
including steroids in some cases as well as dose modifications as recommended by protocol; in most 
cases, they did not lead to treatment discontinuation. Additionally, in the parent DUO study, dose 
modifications (interruptions and reductions) did not significantly impact efficacy outcomes with 
duvelisib in a subset of patients with demographic characteristics comparable to those of the rest of the 
population and allowed patients to remain on treatment (23). 
 
Despite the availability of several novel agents that are active in CLL, additional treatment options are 
needed for this disease. In this study, duvelisib demonstrated effectiveness in patients who had received 
≥ 1 prior therapy before being enrolled in the DUO trial and had then progressed after ofatumumab 
therapy. Additionally, PFS in the subgroup of patients with del(17p) and/or TP53 mutations was similar 
to that for the whole population, which is in contrast to the shorter PFS outcomes reported in patients 
with del(17p) and/or TP53 mutations treated with ibrutinib or venetoclax (4,24). Even among heavily 
pretreated patients who had received ≥ 2 lines of prior therapy, the majority responded to duvelisib 
(ORR, 79%), with a decreased risk of progression in nearly all high-risk patient subgroups (25). 
 
A limitation of our study is that, compared with when the study was initiated, ofatumumab is being used 
less commonly as monotherapy for R/R CLL. Nonetheless, we anticipate that the results observed in the 
patients in our study are likely to be similar to patients who have progressed after regimens containing 
other anti-CD20 monoclonal antibodies, such as obinutuzumab (26). None of the patients in this study 
had previously received a BTK or BCL2 inhibitor, although preclinical data suggest that duvelisib has 
inhibitory activity in CLL cells in the presence of BTK resistance mutations (27) and efficacy in a BTK 
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C481S animal model of CLL (10). Therefore, further studies of duvelisib following BTK inhibitors and 
venetoclax therapies are warranted. 
 
In summary, our study provides additional evidence that duvelisib is effective and tolerable in difficult-
to-treat patients with R/R CLL/SLL. These results confirm duvelisib as an effective, all-oral treatment 
option in CLL/SLL and support the development of further prospective studies of the drug both as a 
single agent and in combination regimens. 
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(n = 90) 
Median age (range), years 
≥ 65 years, n (%) 
68 (39-90) 
55 (61) 
Male, n (%) 57 (63) 








ECOG PS 2, n (%) 10 (11) 
Diagnosis of CLL/SLL, n (%) 89 (99)/1(1) 
Median time from initial diagnosis (range), years 7.1 (0.5-22) 
Median time from most recent R/R diagnosis (range), months 0.9 (0-16.6) 




del(17p) and/or TP53 mutations 









Bulky disease, n (%) 
≥ 5-cm target lesion 




Median baseline lymphocytes (range), × 10
9
/L  14.4 (0-273.2) 
Median baseline hemoglobin (range), g/L 124 (67-176) 
Median baseline platelets (range), × 10
9
/L 122 (16-272) 
Rai stage: diagnosis (n = 41)/enrollment in parent DUO study  









14 (34)/9 (21) 
11 (27)/13 (30) 
1 (2)/4 (9) 
8 (20)/17 (40) 
Binet stage: diagnosis (n = 47)/enrollment in parent DUO study 







26 (55)/33 (70) 
5 (11)/14 (30) 
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(n = 90) 
del(17p) and/or TP53 
Mutations 
(n = 26) 
No Prior Response on 
Ofatumumab 
(n = 64) 









Best overall response, n (%)    
CR 0 0 0 
CRi
b
 4 (4) 3 (12) 1 (2) 
PR 55 (61) 15 (58) 40 (63) 
PRwL 10 (11) 2 (8) 6 (9) 
Stable disease 13 (14) 4 (15) 11 (17) 
PD 1 (1) 0 1 (2) 
Other
c 7 (8) 2 (8) 5 (8) 














Table 2. Response by investigator. a Binominal method. b Patients with CLL only. c Includes unknown 
responses due to missing, incomplete, or inadequate data; no evidence of disease if radiological and 
clinical data indicated no disease involvement; not evaluable if no target lesions were identified at 
baseline and the radiological and clinical data after baseline did not support the disease response of PD 
or unknown. d Patients with a response (all patients: n = 26 [before crossover], n = 69 [after crossover]; 
del(17p) and/or TP53 mutations: n = 7 [before crossover], n = 20 [after crossover]). 
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(n = 90) 
Any Grade Grade ≥ 3 
Any TEAE, n (%) 90 (100) 80 (89) 
Hematologic TEAEs in > 5% of patients, n (%)   
Neutropenia 23 (26) 21 (23) 
Thrombocytopenia 9 (10) 5 (6) 
Anemia 7 (8) 2 (2) 
Nonhematologic TEAEs in ≥ 10% of patients, n (%)   
Diarrhea 42 (47) 21 (23) 
Pyrexia 22 (24) 4 (4) 
Rash 21 (23) 4 (4) 
Colitis 12 (13) 10 (11) 
Pneumonia 12 (13) 10 (11) 
Cough 12(13) 0 
Asthenia 11 (12) 0 
Abdominal pain 10 (11) 1 (1) 
Vomiting 10 (11) 0 
Decreased appetite 9 (10) 0 
Nausea 9 (10) 0 
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Figure 1. A, Median changes from baseline in ALC and the sum of products of diameters (SPD) of target 
nodal lesions over time (n = 78).  
 
Figure 1. B, Best percent change in the SPD of nodal target lesions per investigator (n = 78). aSome 
patients had the cycle 4-day 1 assessment at approximately month 2. bThe upper CI for ALC at 20 
months exceeded 225% (443%). 
 
Figure 2. Progression-free survival in the study population and subgroup of patients with del(17p) 
and/or TP53 mutations. 
 
Figure 3. Rates of grade ≥ 3 AESI and AESI leading to discontinuation in the study population. 
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